Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 9;2022(1):272-276.
doi: 10.1182/hematology.2022000373.

Long-term health outcomes following curative therapies for sickle cell disease

Rohini Chakravarthy  1 , Debra L Friedman  1
Affiliations

Long-term health outcomes following curative therapies for sickle cell disease

Rohini Chakravarthy et al. Hematology Am Soc Hematol Educ Program. .

Abstract

Treatment options for patients with sickle cell disease (SCD) continue to rapidly expand and evolve. The goal of therapies such as an allogeneic hematopoietic stem cell transplant (HSCT), gene therapy, and gene editing is to cure rather than control SCD. The benefits of these therapies must be accompanied by minimizing long-term adverse health outcomes from SCD and its treatment. SCD can have adverse effects on a variety of organ systems, including the heart, lung, kidney, and reproductive system, leading to high disease burden, morbidity, and premature mortality in both pediatric and adult patients. While curative therapies are being increasingly used, there remains a paucity of data on the long-term health outcomes associated with these treatments in children and adults with SCD. There are data available regarding the effects of HSCT performed largely for malignant diseases, from which data on SCD outcomes may be extrapolated. However, given the significant differences between these 2 populations of patients who undergo HSCT, such extrapolation is imprecise at best. Furthermore, there are currently no published data on long-term health outcomes following gene therapy for SCD due to current short follow-up times. We summarize the limited data reported on health outcomes following HSCT for SCD and emphasize the need for more research within this area.

PubMed Disclaimer

Conflict of interest statement

Rohini Chakravarthy: no competing financial interests to declare.

Debra L. Friedman: no competing financial interests to declare.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Evolution of discovery and treatment options for sickle cell disease.
Figure 2.
Figure 2.
Treatment options for sickle cell disease.
See this image and copyright information in PMC

References

    1. Inusa BPD, Hsu LL, Kohli N, et al.. Sickle cell disease: genetics, pathophysiology, clinical presentation and treatment. Int J Neonatal Screen. 2019;5(2):20. doi:10.3390/ijns5020020 - DOI - PMC - PubMed
    1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4, suppl):S512-S521. doi:10.1016/j.amepre.2009.12.022 - DOI - PubMed
    1. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447-3452. doi:10.1182/blood-2009-07-233700. - DOI - PMC - PubMed
    1. DeBaun MR, Ghafuri DL, Rodeghier M, et al.. Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood. 2019;133(6):615-617. doi:10.1182/blood-2018-10-880575. - DOI - PMC - PubMed
    1. Osunkwo I, Andemariam B, Minniti CP, et al.. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY). Am J Hematol. 2021;96(4):404-417. doi:10.1002/ajh.26063. - DOI - PMC - PubMed

Publication types